Spruce Street Capital LP
Clone Performance
Feb 2026–Jul 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. It tracks 100% of reported value on average across 2 quarters. Past performance does not predict future results.
Portfolio Concentration
28 tracked positions · as of Mar 31, 2026 · Δ vs Dec 31, 2025Portfolio Trend
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 98.8% | $412,715,178 |
| Financial Services | 1.2% | $5,080,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | +2,637,522 | 4,059,054 | $9,173,462 | |
| RLMD | Relmada Therapeutics, Inc. | +2,175,933 | 6,262,114 | $43,584,313 | |
| ANRO | Alto Neuroscience, Inc. | +1,102,366 | 1,325,210 | $29,790,720 | |
| ALEC | Alector, Inc. | +983,082 | 2,101,068 | $4,517,296 | |
| SVRA | Savara Inc | +972,082 | 3,383,175 | $18,472,135 | |
| LXEO | Lexeo Therapeutics, Inc. | +753,593 | 928,593 | $5,330,123 | |
| ENTA | Enanta Pharmaceuticals Inc | +542,911 | 932,598 | $11,778,712 | |
| KALV | KalVista Pharmaceuticals, Inc. | +509,713 | 897,681 | $18,070,318 | |
| CNTA | Centessa Pharmaceuticals plc | +411,852 | 489,849 | $19,456,802 | |
| LBRX | Lb Pharmaceuticals Inc | +370,566 | 1,376,159 | $33,936,080 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | +326,081 | 761,063 | $36,645,183 | |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | +75,837 | 373,274 | $31,325,154 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ALKS | Alkermes plc. | 317,992 | $11,244,197 | |
| CATX | Perspective Therapeutics, Inc. | 2,627,107 | $10,955,036 | |
| ALMS | Alumis Inc. | 392,574 | $8,648,405 | |
| MAZE | Maze Therapeutics, Inc. | 200,000 | $5,970,000 | |
| ANTX | AN2 Therapeutics, Inc. | 1,661,073 | $5,680,869 | |
| HLXC | Helix Acquisition Corp. III | 500,000 | $5,080,000 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 231,585 | $3,388,088 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Reduced | 6,262,114 | $43,584,313 | 10.43% | |
| KNSA |
Kiniksa Pharmaceuticals International, plc
Healthcare
|
Added | 761,063 | $36,645,183 | 8.77% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
Added | 1,376,159 | $33,936,080 | 8.12% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Added | 373,274 | $31,325,154 | 7.50% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Added | 1,325,210 | $29,790,720 | 7.13% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Held | 2,984,125 | $29,692,043 | 7.11% | |
| CNTA |
Centessa Pharmaceuticals plc
Healthcare
|
Added | 489,849 | $19,456,802 | 4.66% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 3,383,175 | $18,472,135 | 4.42% | |
| KALV |
KalVista Pharmaceuticals, Inc.
Healthcare
|
Added | 897,681 | $18,070,318 | 4.33% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Reduced | 245,709 | $14,278,149 | 3.42% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 329,006 | $12,897,035 | 3.09% | |
| SRZN |
Surrozen, Inc./DE
Healthcare
|
Held | 432,040 | $12,585,325 | 3.01% | |
| ENTA |
Enanta Pharmaceuticals Inc
Healthcare
|
Added | 932,598 | $11,778,712 | 2.82% | |
| ALKS |
Alkermes plc.
Healthcare
|
NEW | 317,992 | $11,244,197 | 2.69% | |
| CATX |
Perspective Therapeutics, Inc.
Healthcare
|
NEW | 2,627,107 | $10,955,036 | 2.62% | |
| NERV |
Minerva Neurosciences, Inc.
Healthcare
|
Held | 1,655,500 | $9,974,387 | 2.39% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Added | 4,059,054 | $9,173,462 | 2.20% | |
| ALMS |
Alumis Inc.
Healthcare
|
NEW | 392,574 | $8,648,405 | 2.07% | |
| SABS |
SAB Biotherapeutics, Inc.
Healthcare
|
Held | 2,198,502 | $8,420,262 | 2.02% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Reduced | 422,543 | $6,836,745 | 1.64% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Held | 3,581,603 | $6,017,093 | 1.44% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
NEW | 200,000 | $5,970,000 | 1.43% | |
| ANTX |
AN2 Therapeutics, Inc.
Healthcare
|
NEW | 1,661,073 | $5,680,869 | 1.36% | |
| LXEO |
Lexeo Therapeutics, Inc.
Healthcare
|
Added | 928,593 | $5,330,123 | 1.28% | |
| HLXC |
Helix Acquisition Corp. III
Financial Services
|
NEW | 500,000 | $5,080,000 | 1.22% | |
| ALEC |
Alector, Inc.
Healthcare
|
Added | 2,101,068 | $4,517,296 | 1.08% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 393,701 | $4,047,246 | 0.97% | |
| CRVS |
Corvus Pharmaceuticals, Inc.
Healthcare
|
NEW | 231,585 | $3,388,088 | 0.81% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.